Skip to main content

ORIGINAL RESEARCH article

Front. Physiol., 01 April 2021
Sec. Mitochondrial Research
Volume 12 - 2021 | https://doi.org/10.3389/fphys.2021.646903

MiR-22 Inhibition Alleviates Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy by Targeting the sirt1/PGC-1α Pathway

Runze Wang1,2† Yuerong Xu3† Xiaolin Niu1† Yexian Fang1 Dong Guo1 Jiangwei Chen4 Hanzhao Zhu5 Jiaying Dong1 Ran Zhao1 Ying Wang1 Bingchao Qi1 Gaotong Ren1 Xue Li1* Li Liu2* Mingming Zhang1*
  • 1Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China
  • 2Department of Hematology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China
  • 3Department of Orthodontics, School of Stomatology, The Fourth Military Medical University, Xi'an, China
  • 4Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China
  • 5Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Wang R, Xu Y, Niu X, Fang Y, Guo D, Chen J, Zhu H, Dong J, Zhao R, Wang Y, Qi B, Ren G, Li X, Liu L and Zhang M (2021) MiR-22 Inhibition Alleviates Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy by Targeting the sirt1/PGC-1α Pathway. Front. Physiol. 12:646903. doi: 10.3389/fphys.2021.646903

Received: 28 December 2020; Accepted: 22 February 2021;
Published: 01 April 2021; Retracted: 24 August 2022.

Edited by:

Hao Zhou, People's Liberation Army General Hospital, China

Reviewed by:

Liping Wei, Nankai University, China
Ying Tan, Southern Medical University, China
Download